ArticleJournal of thoracic disease2018

Anti-angiogenic therapy in nonsquamous non-small cell lung cancer (NSCLC) with tyrosine kinase inhibition (TKI) that targets the VEGF receptor (VEGFR): perspective on phase III clinical trials.

Sha'Shonda L Revels et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.